New Technology for Treating Snake Venom

演化之聲
Mar 13
3 min read

Snakebite envenoming claims more than 100,000 human lives every year, yet it remains a medical problem that has long received insufficient attention. Snake venoms consist largely of proteins and include components with both cytotoxic and neurotoxic effects. Cytotoxic venom components damage cell membranes and lead to cell rupture, whereas neurotoxins interfere with neural signaling by binding to receptors involved in neurotransmission. For example, the cobra toxin ScNtx can bind to acetylcholine receptors (AChR) and inhibit their normal function, ultimately disrupting neuromuscular activity.

Cytotoxic snake venom disrupting the lipid bilayer of the cell membrane（圖片來源：Torres SV，採用 CC BY-NC-ND 4.0 授權）

Neurotoxic snake venom binding to neurotransmission receptors（圖片來源：Torres SV，採用 CC BY-NC-ND 4.0 授權）

The traditional treatment for snakebite is antivenom serum containing antibodies against venom toxins. These antibodies bind to venom proteins and block their interaction with cellular targets such as membranes or neurotransmitter receptors. Current antivenoms are produced by injecting small amounts of venom into animals such as horses or sheep, allowing the animals to generate antibodies that are later collected from their blood plasma and purified for medical use. Although this approach has saved countless lives, it still suffers from several limitations. Production costs are high, the quality and effectiveness of antivenom can vary from batch to batch, some venom components are poor at stimulating antibody production, and the serum must be stored and transported under cold-chain conditions, which can be difficult in remote regions.

Recent advances in artificial intelligence have begun to transform many areas of biotechnology, including the development of new therapeutics. In one study, researchers used a deep-learning-based protein design method known as RFdiffusion to create artificial proteins capable of binding to three major classes of cobra venom toxins: short-chain α-neurotoxins, long-chain α-neurotoxins, and cytotoxins belonging to the three-finger toxin family. These designed proteins were engineered to recognize and attach to the toxin molecules, thereby preventing them from interacting with their biological targets. In experiments with mice, venom toxins were first injected and then followed by administration of the designed proteins. The results showed that these artificial proteins could effectively protect the animals from otherwise lethal toxin exposure.

One striking feature of these engineered proteins is their size. Their molecular mass is roughly 10 kilodaltons, which is far smaller than conventional antibodies, whose molecular weight often exceeds 100 kilodaltons. The reduced size allows the designed proteins to penetrate tissues more easily, enabling them to reach venom toxins rapidly and neutralize them before severe damage occurs.

Another important advantage lies in the design process itself. Instead of relying on animal immunization and the lengthy screening of antibody libraries, the researchers used computational modeling to generate protein structures predicted to bind strongly and stably to venom toxins. This approach allows high-affinity proteins to be produced rapidly through simulation, bypassing many of the experimental steps traditionally required to discover effective toxin-binding molecules.

Manufacturing also becomes much simpler. Because these proteins are designed using recombinant DNA technology, they can be produced directly in microorganisms such as Escherichia coli. Microbial fermentation is considerably cheaper and easier to scale than animal-based serum production, and it avoids many of the logistical challenges associated with maintaining large animals for antivenom manufacture.

Taken together, these advances point toward a new generation of antivenom therapies. Artificially designed toxin-binding proteins could complement or even partially replace traditional serum-based treatments, providing more stable, cost-effective, and widely accessible options for managing snakebite envenoming. If further development and clinical testing confirm their effectiveness in humans, this technology could transform the treatment of snakebite and reduce the global burden of this neglected tropical disease.